Header Logo

Connection

MARIA BOTTAZZI to Humans

Back to Details
This is a "connection" page, showing publications MARIA BOTTAZZI has written about Humans.
MARIA BOTTAZZI
Connection Strength
1.064
Humans
  1. A Honduran Prevalence Study on Soil-Transmitted Helminths Highlights Serological Antibodies to Tm-WAP49 as a Diagnostic Marker for Exposure to Human Trichuriasis. Am J Trop Med Hyg. 2025 May 07; 112(5):1017-1025.
    View in: PubMed
    Score: 0.025
  2. From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
    View in: PubMed
    Score: 0.021
  3. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 02; 190:106003.
    View in: PubMed
    Score: 0.020
  4. Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. Annu Rev Med. 2022 01 27; 73:55-64.
    View in: PubMed
    Score: 0.020
  5. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021 09 02; 11(1):17626.
    View in: PubMed
    Score: 0.019
  6. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. Appl Microbiol Biotechnol. 2021 May; 105(10):4153-4165.
    View in: PubMed
    Score: 0.019
  7. SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
    View in: PubMed
    Score: 0.019
  8. COVID-19 in the Americas and the erosion of human rights for the poor. PLoS Negl Trop Dis. 2020 12; 14(12):e0008954.
    View in: PubMed
    Score: 0.019
  9. Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis. 2020 07; 14(7):e0008548.
    View in: PubMed
    Score: 0.018
  10. COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nat Rev Immunol. 2020 07; 20(7):399-400.
    View in: PubMed
    Score: 0.018
  11. Coronavirus vaccine-associated lung immunopathology-what is the significance? Microbes Infect. 2020 10; 22(9):403-404.
    View in: PubMed
    Score: 0.018
  12. I Never Thought I Had "Moral Courage," until COVID-19 Happened. Am J Trop Med Hyg. 2020 08; 103(2):551.
    View in: PubMed
    Score: 0.018
  13. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020 06; 20(6):347-348.
    View in: PubMed
    Score: 0.018
  14. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum Vaccin Immunother. 2020 06 02; 16(6):1239-1242.
    View in: PubMed
    Score: 0.018
  15. Central Latin America: Two decades of challenges in neglected tropical disease control. PLoS Negl Trop Dis. 2020 03; 14(3):e0007962.
    View in: PubMed
    Score: 0.018
  16. Inspiring women scientists in Honduras. EBioMedicine. 2019 Nov; 49:21.
    View in: PubMed
    Score: 0.017
  17. "Running the Gauntlet": Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a "Call to Action". Hum Vaccin Immunother. 2019; 15(10):2235-2242.
    View in: PubMed
    Score: 0.017
  18. Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. Infect Immun. 2018 04; 86(4).
    View in: PubMed
    Score: 0.015
  19. Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
    View in: PubMed
    Score: 0.015
  20. Onchocerca volvulus: The Road from Basic Biology to a Vaccine. Trends Parasitol. 2018 01; 34(1):64-79.
    View in: PubMed
    Score: 0.015
  21. A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
    View in: PubMed
    Score: 0.014
  22. Human anthelminthic vaccines: Rationale and challenges. Vaccine. 2016 06 24; 34(30):3549-55.
    View in: PubMed
    Score: 0.013
  23. Advancing a vaccine to prevent hookworm disease and anemia. Vaccine. 2016 06 03; 34(26):3001-3005.
    View in: PubMed
    Score: 0.013
  24. Advancing a vaccine to prevent human schistosomiasis. Vaccine. 2016 06 03; 34(26):2988-2991.
    View in: PubMed
    Score: 0.013
  25. Status of vaccine research and development of vaccines for Chagas disease. Vaccine. 2016 06 03; 34(26):2996-3000.
    View in: PubMed
    Score: 0.013
  26. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016 06 03; 34(26):2992-2995.
    View in: PubMed
    Score: 0.013
  27. The human hookworm vaccine: recent updates and prospects for success. J Helminthol. 2015 Sep; 89(5):540-4.
    View in: PubMed
    Score: 0.012
  28. Neglected tropical diseases in Central America and Panama: review of their prevalence, populations at risk and impact on regional development. Int J Parasitol. 2014 Aug; 44(9):597-603.
    View in: PubMed
    Score: 0.012
  29. Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis. Hum Vaccin Immunother. 2013 Nov; 9(11):2351-61.
    View in: PubMed
    Score: 0.011
  30. New vaccines for neglected parasitic diseases and dengue. Transl Res. 2013 Sep; 162(3):144-55.
    View in: PubMed
    Score: 0.011
  31. Innovation for the 'bottom 100 million': eliminating neglected tropical diseases in the Americas. Adv Exp Med Biol. 2013; 764:1-12.
    View in: PubMed
    Score: 0.011
  32. Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines. 2012 Sep; 11(9):1043-55.
    View in: PubMed
    Score: 0.010
  33. Fusion of Na-ASP-2 with human immunoglobulin Fc? abrogates histamine release from basophils sensitized with anti-Na-ASP-2 IgE. Parasite Immunol. 2012 Aug-Sep; 34(8-9):404-11.
    View in: PubMed
    Score: 0.010
  34. Chagas disease: "the new HIV/AIDS of the Americas". PLoS Negl Trop Dis. 2012; 6(5):e1498.
    View in: PubMed
    Score: 0.010
  35. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
    View in: PubMed
    Score: 0.010
  36. Advances in vaccines against neglected tropical diseases: enhancing physical stability of a recombinant hookworm vaccine through biophysical and formulation studies. Hum Vaccin Immunother. 2012 Jun; 8(6):765-76.
    View in: PubMed
    Score: 0.010
  37. [Immigration, work and health--social, cultural and best practices in occupational medicine: the views of union patronage]. G Ital Med Lav Ergon. 2011 Apr-Jun; 33(2 Suppl):29-32.
    View in: PubMed
    Score: 0.009
  38. The unfinished public health agenda of chagas disease in the era of globalization. PLoS Negl Trop Dis. 2009 Jul 07; 3(7):e470.
    View in: PubMed
    Score: 0.008
  39. Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm. Expert Rev Vaccines. 2008 Dec; 7(10):1481-92.
    View in: PubMed
    Score: 0.008
  40. An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Rev Vaccines. 2006 Apr; 5(2):189-98.
    View in: PubMed
    Score: 0.007
  41. The Current and Future Burden of Long COVID in the United States. J Infect Dis. 2025 Jul 11; 231(6):1581-1590.
    View in: PubMed
    Score: 0.006
  42. Characteristic profiling of CHO-cell expressed MERS-CoV RBD-Fc. Int J Biol Macromol. 2025 Jun; 311(Pt 2):143678.
    View in: PubMed
    Score: 0.006
  43. Mechanistic insights into the structure-based design of a CspZ-targeting Lyme disease vaccine. Nat Commun. 2025 Apr 07; 16(1):2898.
    View in: PubMed
    Score: 0.006
  44. Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate. PLoS Pathog. 2024 Dec; 20(12):e1012764.
    View in: PubMed
    Score: 0.006
  45. Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
    View in: PubMed
    Score: 0.006
  46. Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins. Viruses. 2024 09 20; 16(9).
    View in: PubMed
    Score: 0.006
  47. What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective? J Infect Dis. 2024 Aug 16; 230(2):382-393.
    View in: PubMed
    Score: 0.006
  48. Parasitic Contamination of Soil in the Southern United States. Am J Trop Med Hyg. 2024 Sep 04; 111(3):506-514.
    View in: PubMed
    Score: 0.006
  49. Vaccine value profile for schistosomiasis. Vaccine. 2025 Oct 03; 64:126020.
    View in: PubMed
    Score: 0.006
  50. The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
    View in: PubMed
    Score: 0.006
  51. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial. Lancet Infect Dis. 2024 Jul; 24(7):760-774.
    View in: PubMed
    Score: 0.006
  52. Environmental Detection of Parasites in the Marginalized Paiute Reservations Compared to a Nearby Area. Am J Trop Med Hyg. 2024 Mar 06; 110(3):457-459.
    View in: PubMed
    Score: 0.006
  53. Host gastric corpus microenvironment facilitates Ascaris suum larval hatching and infection in a murine model. PLoS Negl Trop Dis. 2024 Feb; 18(2):e0011930.
    View in: PubMed
    Score: 0.006
  54. Biophysical and biochemical characterization of a recombinant Lyme disease vaccine antigen, CspZ-YA. Int J Biol Macromol. 2024 Feb; 259(Pt 2):129295.
    View in: PubMed
    Score: 0.006
  55. Optimization and revision of the production process of the Necator americanus glutathione S-transferase 1 (Na-GST-1), the lead hookworm vaccine recombinant protein candidate. Hum Vaccin Immunother. 2014; 10(7):1914-25.
    View in: PubMed
    Score: 0.006
  56. Controlled Infection of Humans with the Hookworm Parasite Necator americanus to Accelerate Vaccine Development : The Human Hookworm Vaccination/Challenge Model (HVCM). Curr Top Microbiol Immunol. 2024; 445:367-377.
    View in: PubMed
    Score: 0.006
  57. Vaccine value profile for Hookworm. Vaccine. 2024 07 25; 42(19 Suppl 1):S25-S41.
    View in: PubMed
    Score: 0.006
  58. Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis. Vaccine. 2023 11 03; 41 Suppl 2:S176-S179.
    View in: PubMed
    Score: 0.006
  59. Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis. Vaccine. 2023 08 23; 41(37):5400-5411.
    View in: PubMed
    Score: 0.006
  60. A short-term method to evaluate anti-leishmania drugs by inhibition of stage differentiation in Leishmania mexicana using flow cytometry. Exp Parasitol. 2023 Jun; 249:108519.
    View in: PubMed
    Score: 0.005
  61. A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. PLoS Negl Trop Dis. 2023 03; 17(3):e0011236.
    View in: PubMed
    Score: 0.005
  62. Estimation of the morbidity and mortality of congenital Chagas disease: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2022 11; 16(11):e0010376.
    View in: PubMed
    Score: 0.005
  63. Executive Summary: Insights from Cuba's COVID-19 Vaccine Enterprise: Report from a High Level Fact-Finding Delegation to Cuba. MEDICC Rev. 2022 10 31; 24(3-4):109-128.
    View in: PubMed
    Score: 0.005
  64. Full Technical Report: Insights from Cuba's COVID-19 Vaccine Enterprise: Report from a High Level Fact-Finding Delegation to Cuba. MEDICC Rev. 2022 10 31; 24(3-4):72-108.
    View in: PubMed
    Score: 0.005
  65. Investigation of urinary metabolomics in a phase I hookworm vaccine trial in Gabon. PLoS One. 2022; 17(9):e0275013.
    View in: PubMed
    Score: 0.005
  66. The Lancet Commission on lessons for the future from the COVID-19 pandemic. Lancet. 2022 10 08; 400(10359):1224-1280.
    View in: PubMed
    Score: 0.005
  67. Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. Expert Rev Vaccines. 2022 10; 21(10):1405-1417.
    View in: PubMed
    Score: 0.005
  68. Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Rev Vaccines. 2022 09; 21(9):1185-1203.
    View in: PubMed
    Score: 0.005
  69. Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi. Front Cell Infect Microbiol. 2022; 12:869039.
    View in: PubMed
    Score: 0.005
  70. Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. Lancet Public Health. 2022 04; 7(4):e356-e365.
    View in: PubMed
    Score: 0.005
  71. Biochemical Screening of Potent Zika Virus Protease Inhibitors. ChemMedChem. 2022 04 20; 17(8):e202100695.
    View in: PubMed
    Score: 0.005
  72. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci Transl Med. 2022 Jan 26; 14(629):eabj5305.
    View in: PubMed
    Score: 0.005
  73. ASCVac-1, a Multi-Peptide Chimeric Vaccine, Protects Mice Against Ascaris suum Infection. Front Immunol. 2021; 12:788185.
    View in: PubMed
    Score: 0.005
  74. Transient Ascaris suum larval migration induces intractable chronic pulmonary disease and anemia in mice. PLoS Negl Trop Dis. 2021 12; 15(12):e0010050.
    View in: PubMed
    Score: 0.005
  75. Distinct effects of mitogens and the actin cytoskeleton on CREB and pocket protein phosphorylation control the extent and timing of cyclin A promoter activity. Mol Cell Biol. 2001 Nov; 21(22):7607-16.
    View in: PubMed
    Score: 0.005
  76. Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification study. Lancet Microbe. 2021 Nov; 2(11):e617-e626.
    View in: PubMed
    Score: 0.005
  77. Diversity, Equity, and Inclusion in the Microbial Sciences-the Texas Perspective. mBio. 2021 10 26; 12(5):e0262021.
    View in: PubMed
    Score: 0.005
  78. Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. PLoS Negl Trop Dis. 2021 10; 15(10):e0009732.
    View in: PubMed
    Score: 0.005
  79. Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. J Infect Dis. 2021 09 17; 224(6):938-948.
    View in: PubMed
    Score: 0.005
  80. Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. PLoS Med. 2021 09; 18(9):e1003772.
    View in: PubMed
    Score: 0.005
  81. Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2021 09; 15(9):e0009689.
    View in: PubMed
    Score: 0.005
  82. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
    View in: PubMed
    Score: 0.005
  83. Alterations to the Cardiac Metabolome Induced by Chronic T. cruzi Infection Relate to the Degree of Cardiac Pathology. ACS Infect Dis. 2021 06 11; 7(6):1638-1649.
    View in: PubMed
    Score: 0.005
  84. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. Am J Prev Med. 2021 05; 60(5):605-613.
    View in: PubMed
    Score: 0.005
  85. Preparing for SARS-CoV-2 Vaccines in US Immigrant Communities: Strategies for Allocation, Distribution, and Communication. Am J Public Health. 2021 Apr; 111(4):577-581.
    View in: PubMed
    Score: 0.005
  86. Mining the Metabolome for New and Innovative Chagas Disease Treatments. Trends Pharmacol Sci. 2021 01; 42(1):1-3.
    View in: PubMed
    Score: 0.005
  87. Host Immunity and Inflammation to Pulmonary Helminth Infections. Front Immunol. 2020; 11:594520.
    View in: PubMed
    Score: 0.005
  88. A new patient registry for Chagas disease. PLoS Negl Trop Dis. 2020 10; 14(10):e0008418.
    View in: PubMed
    Score: 0.005
  89. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
    View in: PubMed
    Score: 0.005
  90. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. Lancet Infect Dis. 2021 02; 21(2):275-285.
    View in: PubMed
    Score: 0.005
  91. A scalable and reproducible manufacturing process for Phlebotomus papatasi salivary protein PpSP15, a vaccine candidate for leishmaniasis. Protein Expr Purif. 2021 01; 177:105750.
    View in: PubMed
    Score: 0.005
  92. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. Am J Prev Med. 2020 10; 59(4):493-503.
    View in: PubMed
    Score: 0.004
  93. Disproportionate impact of the COVID-19 pandemic on immigrant communities in the United States. PLoS Negl Trop Dis. 2020 07; 14(7):e0008484.
    View in: PubMed
    Score: 0.004
  94. Use of Multi-Parallel Real-Time Quantitative PCR to Determine Blastocystis Prevalence and Association with Other Gastrointestinal Parasite Infection in a Rural Honduran Location. Am J Trop Med Hyg. 2020 06; 102(6):1373-1375.
    View in: PubMed
    Score: 0.004
  95. The Factor H-Binding Site of CspZ as a Protective Target against Multistrain, Tick-Transmitted Lyme Disease. Infect Immun. 2020 04 20; 88(5).
    View in: PubMed
    Score: 0.004
  96. The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes Infect. 2020 May - Jun; 22(4-5):165-167.
    View in: PubMed
    Score: 0.004
  97. Will COVID-19 become the next neglected tropical disease? PLoS Negl Trop Dis. 2020 04; 14(4):e0008271.
    View in: PubMed
    Score: 0.004
  98. The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020 04 03; 38(16):3261-3270.
    View in: PubMed
    Score: 0.004
  99. Protective immunity elicited by the nematode-conserved As37 recombinant protein against Ascaris suum infection. PLoS Negl Trop Dis. 2020 02; 14(2):e0008057.
    View in: PubMed
    Score: 0.004
  100. The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age. Am J Prev Med. 2020 03; 58(3):370-377.
    View in: PubMed
    Score: 0.004
  101. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.004
  102. Response to `letter to the editor: 'Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America'?. Expert Rev Anti Infect Ther. 2019 09; 17(9):673-675.
    View in: PubMed
    Score: 0.004
  103. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2019 05; 13(5):e0007413.
    View in: PubMed
    Score: 0.004
  104. Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
    View in: PubMed
    Score: 0.004
  105. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Rev Anti Infect Ther. 2019 03; 17(3):145-157.
    View in: PubMed
    Score: 0.004
  106. China's shifting neglected parasitic infections in an era of economic reform, urbanization, disease control, and the Belt and Road Initiative. PLoS Negl Trop Dis. 2019 01; 13(1):e0006946.
    View in: PubMed
    Score: 0.004
  107. Advancing the Development of a Human Schistosomiasis Vaccine. Trends Parasitol. 2019 02; 35(2):104-108.
    View in: PubMed
    Score: 0.004
  108. Ligand binding properties of two Brugia malayi fatty acid and retinol (FAR) binding proteins and their vaccine efficacies against challenge infection in gerbils. PLoS Negl Trop Dis. 2018 10; 12(10):e0006772.
    View in: PubMed
    Score: 0.004
  109. Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production. Parasite Immunol. 2018 Nov; 40(11):e12585.
    View in: PubMed
    Score: 0.004
  110. Lessons along the Critical Path: Developing Vaccines against Human Helminths. Trends Parasitol. 2018 09; 34(9):747-758.
    View in: PubMed
    Score: 0.004
  111. Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. PLoS Negl Trop Dis. 2018 01; 12(1):e0006240.
    View in: PubMed
    Score: 0.004
  112. Human Intestinal Parasite Burden and Poor Sanitation in Rural Alabama. Am J Trop Med Hyg. 2017 Nov; 97(5):1623-1628.
    View in: PubMed
    Score: 0.004
  113. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. PLoS Negl Trop Dis. 2017 05; 11(5):e0005574.
    View in: PubMed
    Score: 0.004
  114. Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci. 2017 08; 106(8):1961-1970.
    View in: PubMed
    Score: 0.004
  115. Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine. PLoS Negl Trop Dis. 2017 02; 11(2):e0005385.
    View in: PubMed
    Score: 0.004
  116. The Global Economic and Health Burden of Human Hookworm Infection. PLoS Negl Trop Dis. 2016 09; 10(9):e0004922.
    View in: PubMed
    Score: 0.003
  117. The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice. PLoS Negl Trop Dis. 2016 07; 10(7):e0004797.
    View in: PubMed
    Score: 0.003
  118. Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. Vaccine. 2016 Apr 27; 34(19):2197-206.
    View in: PubMed
    Score: 0.003
  119. The BENEFIT Trial: Where Do We Go from Here? PLoS Negl Trop Dis. 2016 Feb; 10(2):e0004343.
    View in: PubMed
    Score: 0.003
  120. Identification and Characterization of the Trypanosoma cruzi B-cell Superantigen Tc24. Am J Trop Med Hyg. 2016 Jan; 94(1):114-121.
    View in: PubMed
    Score: 0.003
  121. Identification of immunodominant antigens for the laboratory diagnosis of toxocariasis. Trop Med Int Health. 2015 Dec; 20(12):1787-96.
    View in: PubMed
    Score: 0.003
  122. New Vaccines for the World's Poorest People. Annu Rev Med. 2016; 67:405-17.
    View in: PubMed
    Score: 0.003
  123. Neglected tropical diseases among the Association of Southeast Asian Nations (ASEAN): overview and update. PLoS Negl Trop Dis. 2015 Apr; 9(4):e0003575.
    View in: PubMed
    Score: 0.003
  124. Limited antigenic variation in the Trypanosoma cruzi candidate vaccine antigen TSA-1. Parasite Immunol. 2014 Dec; 36(12):708-12.
    View in: PubMed
    Score: 0.003
  125. Development of chagas cardiac manifestations among Texas blood donors. Am J Cardiol. 2015 Jan 01; 115(1):113-7.
    View in: PubMed
    Score: 0.003
  126. Trypanosoma cruzi screening in Texas blood donors, 2008-2012. Epidemiol Infect. 2016 Apr; 144(5):1010-3.
    View in: PubMed
    Score: 0.003
  127. Toxocariasis in North America: a systematic review. PLoS Negl Trop Dis. 2014 Aug; 8(8):e3116.
    View in: PubMed
    Score: 0.003
  128. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect. 2014 Jul; 16(7):529-31.
    View in: PubMed
    Score: 0.003
  129. A scoping review and prevalence analysis of soil-transmitted helminth infections in Honduras. PLoS Negl Trop Dis. 2014; 8(1):e2653.
    View in: PubMed
    Score: 0.003
  130. Advancing a multivalent 'Pan-anthelmintic' vaccine against soil-transmitted nematode infections. Expert Rev Vaccines. 2014 Mar; 13(3):321-31.
    View in: PubMed
    Score: 0.003
  131. An unfolding tragedy of Chagas disease in North America. PLoS Negl Trop Dis. 2013; 7(10):e2300.
    View in: PubMed
    Score: 0.003
  132. A research capacity strengthening project for infectious diseases in Honduras: experience and lessons learned. Glob Health Action. 2013 Aug 07; 6:21643.
    View in: PubMed
    Score: 0.003
  133. The Human Hookworm Vaccine. Vaccine. 2013 Apr 18; 31 Suppl 2:B227-32.
    View in: PubMed
    Score: 0.003
  134. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013 Apr; 13(4):342-8.
    View in: PubMed
    Score: 0.003
  135. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec; 11(12):1405-13.
    View in: PubMed
    Score: 0.003
  136. The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. Vaccine. 2013 Jan 07; 31(3):480-6.
    View in: PubMed
    Score: 0.003
  137. Modeling the economic value of a Chagas' disease therapeutic vaccine. Hum Vaccin Immunother. 2012 Sep; 8(9):1293-301.
    View in: PubMed
    Score: 0.003
  138. Texas and Mexico: sharing a legacy of poverty and neglected tropical diseases. PLoS Negl Trop Dis. 2012; 6(3):e1497.
    View in: PubMed
    Score: 0.003
  139. Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine. Infect Immun. 2012 Apr; 80(4):1606-14.
    View in: PubMed
    Score: 0.003
  140. Ac-AP-12, a novel factor Xa anticoagulant peptide from the esophageal glands of adult Ancylostoma caninum. Mol Biochem Parasitol. 2011 May; 177(1):42-8.
    View in: PubMed
    Score: 0.002
  141. Expression, purification, crystallization and preliminary X-ray analysis of a truncated soluble domain of human glioma pathogenesis-related protein 1. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Nov 01; 66(Pt 11):1487-9.
    View in: PubMed
    Score: 0.002
  142. Potency testing for the experimental Na-GST-1 hookworm vaccine. Expert Rev Vaccines. 2010 Oct; 9(10):1219-30.
    View in: PubMed
    Score: 0.002
  143. Molecular cloning, biochemical characterization, and partial protective immunity of the heme-binding glutathione S-transferases from the human hookworm Necator americanus. Infect Immun. 2010 Apr; 78(4):1552-63.
    View in: PubMed
    Score: 0.002
  144. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. FASEB J. 2009 Sep; 23(9):3007-19.
    View in: PubMed
    Score: 0.002
  145. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis. 2008 Sep 24; 2(9):e300.
    View in: PubMed
    Score: 0.002
  146. In vitro cultured peripheral blood mononuclear cells from patients with chronic schistosomiasis mansoni show immunomodulation of cyclin D1,2,3 in the presence of soluble egg antigens. Microbes Infect. 2007 Oct; 9(12-13):1493-9.
    View in: PubMed
    Score: 0.002
  147. Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells. Oncogene. 2007 Aug 02; 26(35):5060-9.
    View in: PubMed
    Score: 0.002
  148. New technologies for the control of human hookworm infection. Trends Parasitol. 2006 Jul; 22(7):327-31.
    View in: PubMed
    Score: 0.002
  149. The impact of concurrent and treated Ancylostoma ceylanicum hookworm infections on the immunogenicity of a recombinant hookworm vaccine in hamsters. J Infect Dis. 2006 Jan 01; 193(1):155-62.
    View in: PubMed
    Score: 0.002
  150. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials. Vaccine. 2005 Sep 15; 23(39):4754-64.
    View in: PubMed
    Score: 0.002
  151. Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals. FASEB J. 2005 Oct; 19(12):1743-5.
    View in: PubMed
    Score: 0.002
  152. Hookworm: "the great infection of mankind". PLoS Med. 2005 Mar; 2(3):e67.
    View in: PubMed
    Score: 0.002
  153. The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene. 2005 Jan 20; 24(4):525-40.
    View in: PubMed
    Score: 0.002
  154. Helminth infections of children: prospects for control. Adv Exp Med Biol. 2005; 568:135-44.
    View in: PubMed
    Score: 0.002
  155. Mechanisms of HTLV-1 transformation. Front Biosci. 2004 Sep 01; 9:2347-72.
    View in: PubMed
    Score: 0.001
  156. Role of viral regulatory and accessory proteins in HIV-1 replication. Front Biosci. 2004 Sep 01; 9:2388-413.
    View in: PubMed
    Score: 0.001
  157. Hookworm infection. N Engl J Med. 2004 Aug 19; 351(8):799-807.
    View in: PubMed
    Score: 0.001
  158. The role of cyclin D2 and p21/waf1 in human T-cell leukemia virus type 1 infected cells. Retrovirology. 2004 Apr 13; 1:6.
    View in: PubMed
    Score: 0.001
  159. Protein profile of tax-associated complexes. J Biol Chem. 2004 Jan 02; 279(1):495-508.
    View in: PubMed
    Score: 0.001
  160. Progress in the development of a recombinant vaccine for human hookworm disease: the Human Hookworm Vaccine Initiative. Int J Parasitol. 2003 Sep 30; 33(11):1245-58.
    View in: PubMed
    Score: 0.001
  161. Alpha5beta1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. Mol Biol Cell. 1999 Oct; 10(10):3197-204.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.